Sign in
Active, not recruitingNo phase

Postoperative Thrombosis Prevention in Patients With CD

Key facts

Who runs it
Huashan Hospital
Where
China7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
206 people, planned
Started
1 Dec 2020
Ended
1 Jul 2025
Type of study
Interventional, 2 groups
Treatments tested
  • LMWH/Rivaroxaban
  • IPC
Record updated
2 July 2025

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Cushing\'s disease diagnosed and treated with transsphenoid surgery at study centers

Who cannot take part

  • History of VTE before surgery or within 24 hours post-surgery
  • Major bleeding events
  • History of stroke
  • High risk of bleeding due to clotting abnormalities
  • Presence of other malignant diseases
  • Severe mental or neurological disorders
  • Any other condition that researchers deem inappropriate for study participation
  • Contraindications to rivaroxaban (e.g., renal dysfunction with eGFR \< 50 mL/min)
  • Acute bacterial endocarditis
  • Thrombocytopenia
  • Active gastrointestinal ulcers
  • Participation in other clinical trials within the last three months
  • Presence of intracranial vascular abnormalities
  • Contraindications to mechanical prophylactic anticoagulation
  • Pregnancy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Patients with Cushing disease was randomized to 2 groups. After surgery, the patients were managed with mechanical prevention or mechanical prevention plus anticoagulant drugs(LMWH followed by rivaroxaban), VTE was observed 24h, 5day, 4weeks and 12weeks after surgery.Bleeding events were also recorded.

The 2 groups in the trial

  • mechanical preventionOther group

    patients were managed with IPC

    Treatment: IPC

  • mechanical plus anticoagulant drugs preventionOther group

    patients were managed with IPC, and LMWH was added 24h after surgery and followed by rivaroxaban 5 days after surgery

    Treatment: LMWH/Rivaroxaban and IPC

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective, Multicenter, Randomized Controlled Study of Postoperative Initiation of Thromboprophylaxis in Patients With Cushing's Disease
Publications
Record updated
2 July 2025